Ivabradin Medical Valley (Ivabradine)

Ivabradine selectively blocks the funny (If) current in the sino‑atrial node, the heart’s natural pacemaker. Inhibiting this current slows the spontaneous depolarisation of pacemaker cells, leading to a reduced heart rate without decreasing the strength of cardiac contraction or blood pressure.

The specific dose of Ivabradin Medical Valley is determined by the prescribing clinician based on the patient’s clinical condition, heart‑rate targets, and any concomitant therapies. Dosage adjustments are made according to individual response and tolerability.

Safety data for ivabradine in pregnancy and lactation are limited. It is generally advised to avoid use unless the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Both ivabradine and beta‑blockers lower heart rate, but they act via different mechanisms. Ivabradine selectively inhibits the If current without affecting myocardial contractility or blood pressure, whereas beta‑blockers block adrenergic receptors and can also reduce contractility. Ivabradine is often used when beta‑blockers are contraindicated or insufficient.

Store Ivabradin Medical Valley at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct light, and ensure the container is tightly closed to maintain stability.

Ivabradin Medical Valley is taken orally, usually with a glass of water. The tablet should be swallowed whole and not crushed or chewed. Dosing times are typically spaced to maintain consistent plasma concentrations, as directed by the prescribing physician.

The most serious risks include severe bradycardia, which can lead to dizziness, syncope or heart‑failure worsening, and atrial fibrillation or other arrhythmias. Persistent visual disturbances and rare allergic reactions are also considered serious and require immediate medical evaluation.

Ivabradine should be avoided in patients with a resting heart rate below 60 bpm, those with acute decompensated heart failure, severe hypotension, sick sinus syndrome, or advanced atrioventricular block without a pacemaker. It is also contraindicated in individuals taking strong CYP3A4 inhibitors without dose adjustment.